SeaSpine - SPNE Stock Forecast, Price & News

SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. It offers orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. The company's orthobiologics products include demineralized bone matrix (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. It also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. In addition, the company offers implant products for spinal decompression, alignment, stabilization, and image-guided surgical solutions, as well as a surgical navigation system used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.

SeaSpine Price Performance

Shares of NASDAQ:SPNE traded up $0.33 during midday trading on Friday, hitting $7.17. The stock had a trading volume of 4,623 shares, compared to its average volume of 154,642. SeaSpine has a 1 year low of $5.54 and a 1 year high of $17.34. The company has a market capitalization of $266.65 million, a PE ratio of -3.79 and a beta of 1.39. The company has a quick ratio of 1.67, a current ratio of 3.49 and a debt-to-equity ratio of 0.09. The stock has a 50 day simple moving average of $6.37 and a 200-day simple moving average of $9.25.

SeaSpine (NASDAQ:SPNE - Get Rating) last announced its quarterly earnings data on Tuesday, August 2nd. The medical equipment provider reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.03). SeaSpine had a negative return on equity of 21.90% and a negative net margin of 32.03%. During the same period in the previous year, the company posted ($0.34) EPS. On average, sell-side analysts expect that SeaSpine will post -1.43 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on the company. Piper Sandler dropped their price objective on SeaSpine from $21.00 to $12.00 and set an "overweight" rating on the stock in a report on Wednesday, August 3rd. Truist Financial dropped their price objective on SeaSpine from $20.00 to $12.00 and set a "buy" rating on the stock in a report on Wednesday, July 20th. Cantor Fitzgerald dropped their price objective on SeaSpine from $27.00 to $21.00 and set an "overweight" rating on the stock in a report on Friday, April 22nd. StockNews.com raised SeaSpine from a "sell" rating to a "hold" rating in a report on Thursday, August 4th. Finally, BTIG Research dropped their price objective on SeaSpine from $23.00 to $19.00 in a report on Thursday, June 30th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $30.00.

Insider Buying and Selling

In related news, insider Beau Standish sold 50,000 shares of SeaSpine stock in a transaction that occurred on Thursday, July 14th. The stock was sold at an average price of $5.73, for a total transaction of $286,500.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 9.32% of the stock is currently owned by company insiders.